National Cancer Institute (NCI): all 3,554 studies

Page 18 of 36. Open to participants first (334), then studies with results posted, then the rest; newest registration first within each.

• Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S01)Active, not recruitingNCT06498661Not applicable
• A Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants With Primary Colorectal or Gastroesophageal CancerWithdrawnNCT06410534Phase 2
• Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M)WithdrawnNCT06400264Phase 2
• Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Subprotocol Z1L)Active, not recruitingNCT06400225Phase 2
• Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian CancerWithdrawnNCT06393751Phase 1/2
• Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATCH - Subprotocol M)Active, not recruitingNCT06390865Phase 2
• Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With mTOR Genetic Changes (MATCH - Subprotocol L)Active, not recruitingNCT06385496Phase 2
• Testing the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve Outcomes for Patients With Recurrent GlioblastomaWithdrawnNCT06328036Phase 2
• Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent GlioblastomaSuspendedNCT06325683Phase 2
• Venetoclax for the Treatment of Patients With Relapsed Hairy Cell LeukemiaActive, not recruitingNCT06311227Phase 2
• Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic CancerActive, not recruitingNCT06253520Phase 1
• Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)WithdrawnNCT06210750Phase 2
• Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple MyelomaSuspendedNCT06179888Phase 2
• Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple MyelomaActive, not recruitingNCT06169215Phase 2
• Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell TumorsActive, not recruitingNCT06169124Phase 2
• Erlotinib in Combination With Select Tyrosine Kinase Inhibitors in Adult Patients With Advanced Solid TumorsWithdrawnNCT06161558Phase 1
• Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before SurgerySuspendedNCT06050252Phase 2
• Evaluation of Broccoli Seed and Sprout Extract for Detoxification of Carcinogens in FirefightersActive, not recruitingNCT06009926Phase 2
• Pilot Prospective Study for PET-CT Imaging in Participants With Relapsed/Refractory Acute LeukemiasCompletedNCT05969002
• Olaparib and Alpelisib for Treatment of Metastatic Breast Cancer, A ComboMATCH Treatment TrialWithdrawnNCT05967286Phase 2
• Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX TrialActive, not recruitingNCT05947500Phase 2
• Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal CancerSuspendedNCT05904080Phase 2
• Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal CancerWithdrawnNCT05898828Phase 1/2
• Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamous Cell Carcinoma (SCC) of the Head and Neck: The PANTHERASWithdrawnNCT05879484Phase 1/2
• Study of Rates of Prostate Cancer Diagnosis in Men of African Ancestry Using MRI and MRI Guided BiopsyTerminatedNCT05872503
• Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following TreatmentActive, not recruitingNCT05859334Phase 2
• Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) CancerActive, not recruitingNCT05836584Phase 2
• Testing the Effect of M1774 on Hard-to-Treat Refractory SPOP-mutant Prostate CancerActive, not recruitingNCT05828082Phase 2
• Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA MutationsWithdrawnNCT05807126Phase 1
• Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP)Active, not recruitingNCT05797246Phase 2
• Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell MalignanciesActive, not recruitingNCT05797233Phase 1
• Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine TumorsActive, not recruitingNCT05724108Phase 2
• A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin LymphomaWithdrawnNCT05711628Phase 3
• Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial CancersActive, not recruitingNCT05691504Phase 1
• A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed OsteosarcomaSuspendedNCT05691478Phase 2/3
• CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic CancerSuspendedNCT05685602Phase 1
• Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast CancerSuspendedNCT05673200Phase 1
• Testing the Anti-cancer Drug Darolutamide in Patients With Testosterone-Driven Salivary Gland CancersActive, not recruitingNCT05669664Phase 2
• Evaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung CancerSuspendedNCT05642195Phase 1/2
• Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)Active, not recruitingNCT05638295Phase 2
• Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted TreatmentActive, not recruitingNCT05627245Phase 1
• Longitudinal Early Advance Care Planning Discussions and Documentation (LEADD) Program: An Exploratory Study in Adolescents and Young Adults (AYAs) Receiving Hematopoietic Stem Cell TransplantActive, not recruitingNCT05605574Not applicable
• Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative NeoplasmActive, not recruitingNCT05600894Phase 2
• Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA TrialWithdrawnNCT05564416Phase 2
• Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)Active, not recruitingNCT05564403Phase 2
• Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment TrialActive, not recruitingNCT05554380Phase 2
• Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment TrialActive, not recruitingNCT05554367Phase 2
• Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment TrialActive, not recruitingNCT05554341Phase 2
• Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment TrialActive, not recruitingNCT05554328Phase 2
• Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial CancersActive, not recruitingNCT05538897Phase 1/2
• Feasibility and Preliminary Efficacy of Acceptance and Commitment Therapy (ACT) for Sleep Disturbances in Adults With Sickle Cell Disease (SCD)SuspendedNCT05457790Not applicable
• N-803 Alone or in Combination With BN-Brachyury Vaccine or Bintrafusp Alfa (M7824) for Participants With Castration Resistant Prostate CancerWithdrawnNCT05445882Phase 2
• CAR-Multicenter Analysis (CAR-MA): Retrospective Study to Characterize CAR T-cell Outcomes and Related Toxicities in Children and Young Adults With B-ALLCompletedNCT05440409
• Omics of Cancer: OncoGenomicsWithdrawnNCT05431439
• Testing a Combination of Vaccines for Cancer Prevention in Lynch SyndromeActive, not recruitingNCT05419011Phase 2
• Oral Iloprost for the Prevention of Lung Cancer In Former SmokersWithdrawnNCT05411107Phase 2
• Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic CancerActive, not recruitingNCT05411094Phase 1
• Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 TrialActive, not recruitingNCT05411081Phase 2
• Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive Surgery in Participants With Pleural Mesotheliomas, or Pleural Effusions From Cancers Expressing MesothelinWithdrawnNCT05375825Phase 1
• Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung CancerActive, not recruitingNCT05353439Phase 1
• Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET TrialActive, not recruitingNCT05327010Phase 2
• Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF MutationActive, not recruitingNCT05308446Phase 2
• Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor TherapyWithdrawnNCT05295589Phase 2
• Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient TumorsActive, not recruitingNCT05286801Phase 1/2
• Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or CarcinosarcomaActive, not recruitingNCT05256225Phase 3
• Single-Dose HPV Vaccination for the Prevention of Cervical Cancer in Young Adult Women in Costa Rica, The PRISMA ESCUDDO TrialActive, not recruitingNCT05237947Phase 4
• Testing Obeticholic Acid for Familial Adenomatous PolyposisTerminatedNCT05223036Phase 2
• A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver CancerActive, not recruitingNCT05211323Phase 2
• Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung CancerActive, not recruitingNCT05198830Phase 2
• Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and NeckActive, not recruitingNCT05172258Phase 2
• Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After SurgeryActive, not recruitingNCT05111574Phase 2
• A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)SuspendedNCT05099003Phase 1/2
• Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV StudyActive, not recruitingNCT05092958Phase 3
• Cancer Preventive Vaccine Nous-209 for Lynch Syndrome PatientsActive, not recruitingNCT05078866Phase 1/2
• Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck CancersActive, not recruitingNCT05063552Phase 2/3
• Hyperspectral Analysis of Sweat Metabolite Biometrics for Real-Time Detection of COVID-19TerminatedNCT05044780
• Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung CancerWithdrawnNCT04989283Phase 2
• Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and ImmunotherapyActive, not recruitingNCT04963153Phase 1
• Needs Assessment for Individuals and Families Affected by Dyskeratosis Congenita (DC) and Related Telomere Biology Disorders (TBD)CompletedNCT04959188
• Biospecimen Collection in Identifying Genetic Changes in Patients With Breast, Prostate, Colorectal, Liver, or Kidney Cancer or Multiple Myeloma Undergoing SurgerySuspendedNCT04955808
• Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple MyelomaActive, not recruitingNCT04933539Phase 2
• Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 NegativeActive, not recruitingNCT04929041Phase 2/3
• Therapy Adapted for High Risk and Low Risk HIV-Associated Anal CancerActive, not recruitingNCT04929028Phase 2
• Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults With Relapsed or Refractory Solid TumorsSuspendedNCT04890093Phase 1/2
• Systematically Assessing Changes in Plexiform Neurofibroma Related Disfigurement From Photographs of Subjects With Neurofibromatosis Type 1 on a Phase 2 Clinical TrialCompletedNCT04879160
• The Effect of Diet and Exercise on ImmuNotherapy and the Microbiome (EDEN)SuspendedNCT04866810Not applicable
• Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent/Metastatic Gastric or Head and Neck CancerCompletedNCT04847466Phase 2
• Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain AmyloidosisActive, not recruitingNCT04847453Phase 1
• Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid TumorsSuspendedNCT04840589Phase 1
• A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP InhibitorsCompletedNCT04826341Phase 1/2
• Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or GliosarcomaCompletedNCT04817254Phase 2
• Pilot Study to Investigate Magnetic Resonance (MR) Image Guided Focal Therapy in Prostate CancerSuspendedNCT04808427Not applicable
• Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine CancersActive, not recruitingNCT04802174Phase 1/2
• Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell LymphomaActive, not recruitingNCT04799275Phase 2/3
• Incidence of Malignant Peripheral Nerve Sheath Tumor (MPNST) Development in Participants With Neurofibromatosis Type 1 (NF1) Receiving and Not Receiving Medical Therapies Directed at Plexiform Neurofibromas (PN)CompletedNCT04774289
• Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell LymphomaActive, not recruitingNCT04759586Phase 3
• Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal CancerActive, not recruitingNCT04751370Phase 2
• Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine TumorsActive, not recruitingNCT04750954Phase 1
• NIH-AARP Diet and Health Secondary Research Study Based on OH95CN025 DataActive, not recruitingNCT04750915
• Assessment of Bone Mineral Density in People Living With HIV and KSHV Associated Malignancies: A Retrospective Longitudinal AnalysisActive, not recruitingNCT04742387

← National Cancer Institute (NCI) overview and focus areas